title: Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans of the rat liver.
abstract: OBJECTIVE
  The purpose of this study was to investigate the effect of lapatinib treatment on hepatic parenchymal enhancement on Gd-EOB-MRI scans in rat.
  
  
  METHODS
  Institutional animal review board approval was received prior to the commencement of all studies. Five rats received a single oral dose of 100 mg/kg/day lapatinib for 7 consecutive days. The controls (n = 5) were given 0.5 % (w/v) aqueous hydroxypropyl methyl cellulose containing 0.1 % (v/v) Tween 80 for 7 days. After the acquisition of gadoxetate disodium-enhanced MR images using 0.025 mmol gadolinium/kg, their livers were subjected to pathologic study to determine the expression level of organic anion-transporting polypeptide 1 (oatp1) and multi-drug resistance-associated protein 2 (mrp2).
  
  
  RESULTS
  Relative enhancement of the liver was similar in both groups. At the hepatobiliary phase, which in rats occurs 3 min after the injection of Gd-EOB, it was 0.90 ± 0.06 in lapatinib-treated rats and 0.84 ± 0.08 in the controls (p = 0.30). There was also no difference in the expression level of oatp1 and mrp2.
  
  
  CONCLUSIONS
  In rats, the administration of lapatinib for 7 days had no effect on hepatic parenchymal enhancement on Gd-EOB-MRI scans.
authors.affiliation: Diagnostic Radiology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan. yukon@hiroshima-u.ac.jp
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hirokawa
authors.forename: Shigemi
authors.initials: S
authors.lastname: Kitamura
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamasaki
authors.forename: Koji
authors.initials: K
authors.lastname: Arihiro
authors.forename: Fuminari
authors.initials: F
authors.lastname: Tatsugami
authors.forename: Makoto
authors.initials: M
authors.lastname: Iida
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kakizawa
authors.forename: Shuji
authors.initials: S
authors.lastname: Date
authors.forename: Kazuo
authors.initials: K
authors.lastname: Awai
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D003287:Contrast Media; D019786:Gadolinium DTPA; D015972:Gene Expression Regulation, Neoplastic; D007089:Image Enhancement / Q000379:methods; D000077341:Lapatinib; D008099:Liver / Q000737:chemistry / Q000187:drug effects*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000032:analysis; D027701:Organic Cation Transport Proteins / Q000032:analysis; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D003287:Contrast Media; D019786:Gadolinium DTPA; D000077341:Lapatinib; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D027701:Organic Cation Transport Proteins; D011799:Quinazolines; C451262:Slco1c1 protein, rat; C073590:gadolinium ethoxybenzyl DTPA